Search Results

You are looking at 321 - 330 of 2,911 items for :

  • Refine by Access: All x
Clear All
Full access

HSR22-163: Real World Data and Independent Predictors of Clinical Outcomes with CDK Inhibitors in Metastatic ER+ Breast Cancer Patients

Priyanka Reddy, James Martin, and Alberto Montero

Full access

Treatment of Acute Promyelocytic Leukemia for Older Patients

Thomas Prebet and Steven D. Gore

T he treatment of acute myeloid leukemia (AML) in older patients remains challenging. 1 Both disease- and patient-related factors unfavorably influence patient outcome, with a 2-year probability of overall survival of 10% to 15%. 2 Acute

Full access

VATS Versus Open Surgery for Lung Cancer Resection: Moving Toward a Minimally Invasive Approach

Jacob Klapper and Thomas A. D’Amico

. The thoracoscopic approach is oncologically equivalent to thoracotomy, while resulting in fewer complications, improved quality of life, shorter length of stay, and superior compliance with adjuvant therapies. 6 – 8 Oncologic Outcomes The

Full access

Reducing the Time From Initial Call to First Appointment: The Impact of Patient Access Redesign and a Nurse Navigation Program

Lori J. Goldstein, Bonnie J. Miller, Nancy Nicotera, and Delinda Pendleton

, FCCC’s performance has demonstrated a high level of concordance, based on findings from the NCCN Oncology Outcomes Database project benchmarking data in breast cancer. Access to the NCCN Breast Cancer Timing in Continuation and Transition of Care

Full access

Toward Less-Invasive Management of Early-Stage Breast Cancer

Amy Cyr

modality. This modality allows for more individualized, flexible delivery of radiation and appears to result in less fat necrosis; however, formal data on these and oncologic outcomes are lacking. In a study presented at the ASTRO 2014 Annual Meeting, after

Full access

In the Age of Novel Therapies, What Defines High-Risk Multiple Myeloma?

Ashraf Badros

% of patients survive longer than 10 years, irrespective of therapy. 1 , 2 Genetic variations among myeloma cells appear to underlie much of the heterogeneity in clinical outcomes. Several groups have reported on the prognostic capability of genetic

Full access

Monitoring Minimal Residual Disease in Acute Myeloid Leukemia: Ready for Prime Time?

Farhad Ravandi and Jeffrey L. Jorgensen

molecular abnormalities both in cytogenetically normal and abnormal AML, they are by no means absolute in predicting the outcome. 5 Therefore, more than 35% of patients with “favorable risk” cytogenetics experience relapse, and despite better identification

Full access

Emerging Therapies in the Treatment of Bladder Cancer

Presented by: Arlene O. Siefker-Radtke

stable disease or better after undergoing frontline platinum-based chemotherapy. This recent category 1 recommendation provides clinicians with more options to improve long-term outcomes in the setting of metastatic urothelial cancer. Targeted

Full access

Monitoring Chronic Myelogenous Leukemia in the Age of Tyrosine Kinase Inhibitors

Jerald P. Radich and Vivian Oehler

clinical outcome in chronic myeloid leukaemia . Br J Haematol 2003 ; 120 : 990 – 999 . 23. Branford S Rudzki Z Harper A . Imatinib produces significantly superior molecular responses compared with interferon alfa plus cytarabine in patients

Full access

Management of Primary Central Nervous System Lymphoma

Francois G. El Kamar and Lauren E. Abrey

outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments . J Clin Oncol 2002 ; 20 : 231 – 236 . 21 Ferreri AJ Blay JY Reni M . Prognostic scoring system for primary